Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abcellera Biologics Inc (NQ: ABCL )

2.760 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Abcellera Biologics Inc

< Previous 1 2 3 4 Next >
AbCellera to Present at Upcoming Investor Conferences in December and January
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Reports Q3 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present at Upcoming Investor Conferences in November 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present at Upcoming Investor Conferences in September
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Reports Q2 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Reports Q1 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces Resignation of Board Member
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present at Upcoming Investor Conferences in March
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Reports Full Year 2023 Business Results
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report Full Year 2023 Financial Results on February 20, 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Reports Q3 2023 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
From AbCellera Biologics Inc.
Via Business Wire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
Multi-year collaboration to jointly discover, develop, and commercialize novel oncology medicines for up to five programs, with the first ADC program focusing on a SMARCA degrader 
From Prelude Therapeutics, Inc.; AbCellera
Via GlobeNewswire
AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023
From AbCellera Biologics Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.